J&J Beats and Raises, but Abiomed Hiccup Tests the Growth Narrative

Johnson & Johnson delivered a second-quarter beat, raised its full-year outlook, and reaffirmed its ambition of double-digit growth by the end of the decade. Yet beneath the headline numbers, the quarter revealed a notable divergence: Innovative Medicine surged ahead on the back of new launches, while MedTech, particularly cardiovascular, stumbled on a near-term clinical-data overhang.

We said 2026 would be a year of accelerated growth and impact for Johnson & Johnson, and with our Q2 beat on the top and bottom line and raised guidance, we are delivering.

The company reported operational sales growth of 5.6%, with the U.S. up 7.3%. Excluding the biosimilar headwind from STELARA, the enterprise grew double digits. CFO Joe Wolk raised adjusted operational EPS guidance to $11.50–$11.65, a $0.18 increase at the midpoint.

Innovative Medicine: Launches Deliver

The star of the quarter was ICOTYDE, the first-in-class oral IL-23 peptide for psoriasis. Management provided updated launch metrics that showed rapid acceleration. Jennifer Taubert, Worldwide Chairman of Innovative Medicine, noted:

This is a dramatic escalation from the first quarter, when the company reported roughly 1,000 unique prescribers. The early success reinforces the potential of ICOTYDE as a future blockbuster. Meanwhile, TREMFYA delivered its first $2 billion quarter, growing over 70%, with strong uptake in ulcerative colitis and Crohn's disease. The company's sequential growth across pharma underscores the durability of the portfolio.

MedTech: A Near-Term Setback

MedTech grew only 3.6%, held back by cardiovascular. Electrophysiology was impacted by a China inventory dynamic, and heart recovery—the Abiomed business—slowed sharply. Tim Schmid, MedTech Chairman, addressed the issue directly:

We see this as a near-term dynamic, and we're actively engaging physicians and their teams to reinforce appropriate patient selection, leveraging the significant depth of our clinical evidence base.

The slowdown is attributed to a neutral U.K. trial in high-risk PCI, which has prompted physicians to be more selective. Yet management emphasized that three of the four MedTech businesses—surgery, vision, and orthopedics—actually accelerated. The Abiomed business remains a growth driver in the long term, but the near-term trajectory is uncertain. The company is betting on the PROTECT IV trial, expected in 2027, to restore confidence. Meanwhile, Tim Schmid noted that “Procedure volumes continue to be stable, and we're not seeing evidence of a broad-based slowdown in demand.” — Tim Schmid, Executive Vice President, Worldwide Chairman, MedTech · 2026-07-15 This suggests the MedTech softness is company-specific rather than systemic.

Outlook and Financials

Despite the MedTech hiccup, J&J raised its sales outlook and kept its line-of-sight to a $100 billion revenue year. The company also reaffirmed its commitment to robotics with OTTAVA and MONARCH, and the orthopedics spin-off is on track for mid-2027. The raised guidance reflects strong pharma performance:

Looking at the fundamentals, J&J's revenue has been on a steady upward path. In Q1 2026, total revenue was $24.1B, and the Q2 print of $25.3B confirms the acceleration:

What Changed?

The key change this quarter is the emergence of a near-term risk in MedTech—specifically the Abiomed slowdown—juxtaposed against robust pharma momentum. This contrast sets up the narrative for the rest of the year. Management's confidence is anchored in the breadth of the portfolio, as Joaquin Duato reiterated in the Q1 call:

And Jennifer Taubert, on ICOTYDE, had said in Q1:

The Q2 update shows that trajectory has steepened considerably. As the company heads into the second half, the key question is whether MedTech can recapture its growth, and whether the procedure volumes and evidence base will support a recovery. For now, J&J's diversified model is absorbing the shock, but the market will be watching closely.